Company: FTII
Filing Date: 2025-07-17
Form Type: PRE 14A
Source: 0001641172-25-020051
Chunk: 42

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-07-17
Form: PRE 14A
Chunk 42
---
-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account not previously released to the Company to pay its taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding Offering Shares, which redemption will completely extinguish rights of the public stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Board in accordance with applicable law, dissolve and liquidate, subject in the case of clauses (ii) and (iii) to the Company’s obligations under the DGCL to provide for claims of creditors and the requirements of other applicable law. There will be no distribution from the Trust Account with respect to our warrants which will expire worthless in the event we wind up.

In the event that FutureTech’s stockholders approve an initial business combination at a special meeting and a monthly extension is necessary after the special meeting but prior to the closing of the initial business combination, FutureTech will not make an Extension Payment for such extension for the time period between the special meeting approving an initial business combination and closing the initial business combination.

Since the Company’s securities are quoted on the OTCID over-the-counter market, we could face significant material adverse consequences, including:

● a limited availability of market quotations for our securities;

● reduced liquidity for our securities;

● a determination that our shares of common stock are a “penny stock” which will require brokers trading in our shares of common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

● a limited amount of news and analyst coverage;

● a decreased ability to issue additional securities or obtain additional financing in the future; and

● the Company may be deemed a less attractive merger partner for a target company or business.

| 15 |

We also note that Nasdaq delisting of the Company’s securities from trading on its exchange and the Company is not able to list its securities on another national securities exchange, may affect the Company’s ability to consummate its planned Business Combination with Longevity Biomedical Inc. We note that under the Merger Agreement, (i) the Company made covenant to maintain listing on Nasdaq during the Interim Period (which is from September 16, 2024 to the closing of the